Jervell and Lange-Nielsen Syndrome 2 (JLNS2) Cell Models for Research

Jervell and Lange-Nielsen Syndrome 2 (JLNS2) is an extremely rare autosomal recessive disorder characterized by congenital sensorineural hearing loss and a prolonged QT interval, leading to syncope, ventricular arrhythmias, and sudden cardiac death. The exact prevalence is unknown, but it is estimated to affect 1 in 1 million individuals worldwide (WHO, 2023). The condition is more common in populations with high consanguinity. Without treatment, the mortality rate is high, with many untreated individuals dying before adulthood. Early diagnosis and intervention (beta-blockers, implantable cardioverter-defibrillators) improve outcomes, but the risk of sudden death remains significant.

JLNS2 is an ideal model for studying cardiac ion channel function and arrhythmogenesis. The disease is caused by mutations in the KCNE1 gene, which encodes the minimal potassium channel subunit that modulates the voltage-gated potassium channel KCNQ1. Research on JLNS2 provides insights into the molecular mechanisms of long QT syndrome, cardiac repolarization, and drug-induced arrhythmias. Public datasets, such as ClinVar and the Human Gene Mutation Database, provide a wealth of mutation data, yet many variants remain uncharacterized. Gene-edited cell models offer a powerful platform to study the functional consequences of specific mutations and to test potential therapies.

The primary pathogenic mechanism in JLNS2 is the loss or dysfunction of the KCNE1 protein, which is essential for the proper function of the cardiac slow delayed rectifier potassium current (IKs). This current is crucial for repolarization of the cardiac action potential. The pathway involves:

1. KCNE1 co-assembles with KCNQ1 to form the IKs channel.

2. Mutations in KCNE1 disrupt channel assembly, trafficking, or gating.

3. Reduced IKs current prolongs the action potential duration.

4. Prolonged repolarization increases the risk of early afterdepolarizations and torsades de pointes.

Additionally, KCNE1 mutations may affect other potassium channels, such as KCNH2 (hERG), contributing to the phenotype.

Data from ClinVar and the Human Gene Mutation Database (HGMD).

The primary deregulated network is the cardiac action potential pathway, specifically the IKs current. Key nodes include:

• • KCNQ1 (pore-forming subunit)
• • KCNE1 (regulatory subunit)
• • KCNH2 (hERG, IKr)
• • Beta-adrenergic signaling (PKA phosphorylation of KCNQ1)
• • Calcium/calmodulin-dependent signaling

Dysfunction of IKs leads to an imbalance in repolarization reserve, making the heart more vulnerable to arrhythmias under stress or drug exposure.

Organoids, such as cardiac organoids derived from iPSCs, provide a more physiologically relevant 3D environment and can recapitulate cell-cell interactions and tissue-level phenotypes.

Animal models for JLNS2 include:

• • Knockout mice: Kcne1-/- mice exhibit prolonged QT interval and arrhythmias.
• • Knock-in mice: Mice carrying specific KCNE1 mutations (e.g., p.D76N) recapitulate the human phenotype.
• • Zebrafish: Kcne1 knockdown models show bradycardia and arrhythmias.

These models are valuable for studying disease mechanisms and testing therapeutic interventions.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise mutations in KCNE1. These models include:

• • KCNE1 knockout cell lines: Complete loss of function, mimicking null mutations.
• • KCNE1 knock-in cell lines: Introduction of specific patient mutations (e.g., p.D76N, p.G52R) to study their functional impact.
• • Reporter cell lines: Tagged KCNE1 to track protein expression and localization.

These sequence-verified models are commercially available and accelerate research by providing consistent, reproducible systems. They are essential for studying the molecular consequences of mutations and for drug screening.

Gene-edited cell lines are used to validate the pathogenicity of KCNE1 variants of uncertain significance. For example, a KCNE1 knockout line can be used to confirm that a variant fails to rescue the IKs current when co-expressed with KCNQ1. Knock-in lines with specific mutations allow detailed electrophysiological characterization, such as patch-clamp analysis of current density and gating kinetics.

Isogenic pairs (wild-type vs. mutant) are used to screen for drugs that selectively enhance IKs in mutant cells. This approach can identify compounds that correct the trafficking defect or increase channel open probability. Additionally, these models are used to assess the proarrhythmic risk of drugs, as mutant cells are more susceptible to drug-induced QT prolongation.

CRISPR-based synthetic lethality screens can identify genes that, when silenced, selectively kill KCNE1-mutant cells but not wild-type cells. This can reveal potential therapeutic targets for JLNS2. Furthermore, gene-edited cells can be used to discover biomarkers of disease progression or drug response.